Substituted pyrimidines for inhibiting Raf kinase activity

Patent metadata

Field	Value
Publication number	US-9920048-B2
Application number	US-201615380515-A
Country	US
Kind code	B2
Filing date	Dec 15, 2016
Priority date	Jun 29, 2007
Publication date	Mar 20, 2018
Grant date	Mar 20, 2018

Abstract

The present invention provides methods of inhibiting Raf kinase activity in a patient, the method comprising administering to the patient a compound having formula I:

or a pharmaceutically acceptable salt thereof, wherein R x , R y , R 1 , L 1 , L 2 , Cy 1 , and Cy 2 are as defined as set forth in the specification.

First claim

We claim:

1. A method of inhibiting Raf kinase activity in a patient, or a biological sample, the method comprising administering to said patient, or contacting said biological sample with a compound having formula I:

or a pharmaceutically acceptable salt thereof, wherein:
Cy 1 is a 5-6 membered partially unsaturated or aromatic ring having 1-3 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur;
Cy 2 is a 5-14 membered saturated, partially unsaturated, or aromatic monocyclic, bicyclic, or tricyclic ring having 0-4 heteroatoms, independently selected from the group consisting of nitrogen, oxygen, and sulfur, wherein the ring is substituted with one or two groups independently selected from the group consisting of —R ∘ , -halo, —NO 2 , —CN, —OR ∘ , —SR ∘ , —N(R ∘ ) 2 , —C(O)R ∘ , —CO 2 R ∘ , —C(O)C(O)R ∘ , —C(O)CH 2 C(O)R ∘ , —S(O)R ∘ , —S(O) 2 R ∘ , —C(O)N(R ∘ ) 2 , —S(O) 2 N(R ∘ ) 2 , —OC(O)R ∘ , —N(R ∘ )C(O)R ∘ , —N(R ∘ )N(R ∘ ) 2 , —C═NN(R ∘ ) 2 , —C═NOR ∘ , —N(R ∘ )C(O)N(R ∘ ) 2 , —N(R ∘ )S(O) 2 N(R ∘ ) 2 , —N(R ∘ S(O) 2 R ∘ , and —OC(O)N(R ∘ ) 2 ;
R ∘ is selected from the group consisting of hydrogen, C 1-6 aliphatic, C 1-6 aliphatic substituted by halogen, —CH 2 Ph, —O(CH 2 ) 0-1 Ph, and 4-6 membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur;
L 1 is a straight or branched C 1-6 alkylene chain;
L 2 is a direct bond, or a straight or branched C 1-6 alkylene chain wherein 1 or 2 methylene units of L 2 are optionally and independently replaced by —O—, S—, —N(R)—, —C(O)—, —C(O)N(R)—, —N(R)C(O)N(R)—, —N(R)C(O)—, —N(R)C(O)O—, —OC(O)N(R)—, —S(O) 2 —, —S(O) 2 N(R)—, —N(R)S(O) 2 —, —OC(O)—, or —C(O)O—;
each R is independently hydrogen or a C 1-6 aliphatic group;
R 1 is hydrogen or a C 1-6 aliphatic group;
each of R x and R y is independently selected from the group consisting of —R 2 , -halo, —NO 2 , —CN, —OR 2 , —SR 2 , —N(R 2 ) 2 , —C(O)R 2 , —CO 2 R 2 , —C(O)C(O)R 2 , —C(O)CH 2 C(O)R 2 , —S(O)R 2 , —S(O) 2 R 2 , —S(O) 2 N(R 2 ) 2 , —OC(O)R 2 , —N(R 2 )C(O)R 2 , —N(R 2 )N(R 2 ) 2 , —N(R 2 )—C(═NR 2 )N(R 2 ) 2 , —C(═NR 2 )N(R 2 ) 2 , —C═NOR 2 , —N(R 2 )C(O)N(R 2 ) 2 , —N(R 2 )S(O) 2 N(R 2 ) 2 , —N(R 2 )S(O) 2 R 2 , and —OC(O)N(R 2 ) 2 ; and
each R 2 is independently selected from the group consisting of hydrogen, C 1-6 aliphatic, C 6-10 monocyclic or bicyclic aryl ring, and 5-10 membered saturated, partially unsaturated, or aromatic monocyclic or bicyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or
two R 2 on the same nitrogen are taken together with the nitrogen to form a 5-8 membered saturated, partially unsaturated, or aromatic ring having 1-4 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur.

2. The method according to claim 1 , wherein the patient suffers from a disorder selected from the group consisting of melanoma, leukemia, colon cancer, breast cancer, gastric cancer, ovarian cancer, lung cancer, brain cancer, laryngeal cancer, cervical cancer, renal cancer, cancer of the lymphatic system, cancer of the genitourinary tract, stomach cancer, bone cancer, lymphoma, glioma, papillary thyroid cancer, neuroblastoma, and pancreatic cancer.

3. The method according to claim 1 , wherein each of R x and R y is independently selected from the group consisting of R 2 , halo, —OR 2 , —N(R 2 ) 2 , —OC(O)R 2 , —N(R 2 )C(O)R 2 , —N(R 2 )N(R 2 ) 2 , —N(R 2 )C(O)N(R 2 ) 2 , —N(R 2 )S(O) 2 N(R 2 ) 2 , —N(R 2 )S(O) 2 R 2 , and —OC(O)N(R 2 ) 2 .

4. The method according to claim 1 , wherein R 1 is hydrogen and L 1 is a straight or branched C 1-4 alkylene chain.

5. The method according to claim 1 , wherein Cy 1 is selected from the group consisting of pyrrolyl, pyrazolyl, imidazolyl, triazolyl, thiophenyl, furanyl, thiazolyl, isothiazolyl, thiadiazolyl, oxazolyl, isoxazolyl, and oxadiazolyl.

6. The method according to claim 1 , wherein Cy 2 is selected from the group consisting of phenyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, thiophenyl, furanyl, thiazolyl, isothiazolyl, thiadiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, tetrazinyl, pyrrolidinyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl, imidazopyridinyl, indazolyl, purinyl, cinnolinyl, quinazolinyl, phthalazinyl, naphthyridinyl, quinoxalinyl, benzothiophenyl, and benzofuranyl.

7. The method according to claim 1 , wherein L 2 is a direct bond or a straight or branched C 1-4 alkylene chain wherein 1 methylene unit of L 2 is replaced by —C(O)N(R)—.

8. The method according to claim 1 , wherein L 1 is —CH(CH 3 )— and L 2 is —C(O)N(H)—.

9. The method according to claim 8 , wherein R x is selected from the group consisting of hydrogen and halo.

10. The method according to claim 8 , wherein R y is —N(H) 2 .

11. The method according to claim 8 , wherein Cy 1 is thiazolyl.

12. The method according to claim 8 , wherein Cy 2 is pyridinyl, wherein the substituents are independently selected from the group consisting of Cl, F, CF 3 , and C 1-4 alkyl.

13. The method according to claim 1 , wherein the compound having formula I is:

or a pharmaceutically acceptable salt thereof.

Assignees

• Millennium Pharm Inc
• Sunesis Pharmaceuticals Inc

Inventors

• Chen Weirong
• Cossrow Jennifer
• Franklin Lloyd
• Guan Bing
• Jones John Howard
• Kumaravel Gnanasambandam
• Lane Benjamin
• Littke Adam
• Lugovskoy Alexey
• Peng Hairuo
• Powell Noel
• Raimundo Brian C
• Tanaka Hiroko
• Vessels Jeffrey
• Wynn Thomas
• Xin Zhili

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P35/02

  specific for leukemia · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P7/00

  Drugs for disorders of the blood or the extracellular fluid · CPC title